Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549875 | 0.76 | ALDH1A1 (0.45) | TDP1ALDH1A1LMNARAB9AL3MBTL1 | |
| SCHEMBL29549876 | 0.76 | ALDH1A1 (0.45) | TDP1ALDH1A1LMNARAB9AL3MBTL1 | |
| SCHEMBL30936658 | 0.73 | TDP1 (0.38) | TDP1 | |
| SCHEMBL22445196 | 0.73 | TDP1 (0.38) | TDP1 | |
| SCHEMBL29549805 | 0.71 | ALDH1A1 (0.41) | TDP1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL23530022 | 0.71 | ALDH1A1 (0.41) | TDP1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL29550468 | 0.71 | TDP1 (0.40) | TDP1LMNARAB9A | |
| SCHEMBL29166001 | 0.71 | TDP1 (0.40) | TDP1ALDH1A1LMNARAB9AL3MBTL1 | |
| SCHEMBL23530212 | 0.71 | TDP1 (0.40) | TDP1LMNARAB9A | |
| SCHEMBL25880792 | 0.69 | ENPP1 (0.43) | TDP1ALDH1A1PKMRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021121294-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | TDP1 402/4885ALDH1A1 440/4885PKM 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.